Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Faslodex Is First Launch For Doubled Oncology Sales Force

Executive Summary

AstraZeneca's Faslodex is the first launch to be detailed by the company's recently-expanded oncology sales force, following FDA approval of the estrogen receptor down-regulator April 25

You may also be interested in...

What Not To Do: FDA Reviewer Talks Cancer Drug Development Mistakes

Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.

Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003

AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome

AstraZeneca Ramps Up U.S. Sales Force Before Nexium, Statin Launches

AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts